Al Kuwayt

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma, with rapid tumor growth and symptoms varying by tumor location. The disease is classified using advanced methods like immunohistochemistry and molecular testing to guide prognosis and personalized treatment. Despite standard immunochemotherapy curing 60-70% of patients, many experience treatment failure or relapse, and options after second-line therapies remain limited. This observational study examines treatment patterns, demographic, and clinical characteristics of DLBCL patients in the Middle East and Africa. It includes two patient groups those newly diagnosed and eligible for treatment, and those with relapsed or refractory DLBCL who have failed previous therapies. The study aims to explore access to novel therapies and understand real-world treatment approaches in these regions. Participants will be observed over 22 months, during which researchers will document treatment regimens, patient risk profiles, and access to new treatments. Data collection includes patient demographics, disease characteristics, and treatment outcomes. The study does not involve experimental treatments but gathers detailed information to inform future care strategies for DLBCL patients.

This research aims to evaluate the impact of breath awareness combined with pyramid energy on symptoms of depression and anxiety in people with type 2 diabetes mellitus T2DM. The study addresses the high prevalence of psychological distress in T2DM patients, noting the bidirectional relationship between depression and diabetes. Mindfulness-based interventions like breath awareness and yoga have shown promise in reducing psychological disorders, and this study explores whether practicing breath awareness with a pyramid-shaped device can further enhance mental health and glycemic control. Participants will be randomly assigned to either an intervention group or a control group. The intervention group receives 1 to 2 hours of daily training for six weeks on breath awareness using a pyramid-shaped head cap, guided by a certified trainer. This training includes breath awareness techniques, group discussions on mindful living, and wisdom sharing. The control group continues their usual care recommended by their physicians and will receive breath awareness training after the study ends. The study lasts a total of 12 weeks, with follow-up assessments at 6 and 12 weeks. Participants will undergo evaluations at baseline, 6 weeks, and 12 weeks, including questionnaires measuring anxiety, depression, sleep quality, stress, mindful attention, and quality of life. Blood samples will be collected to assess glycemic control HbA1c, cortisol, lipid profiles, thyroid function, and inflammatory markers. Compliance is monitored through attendance logs. The primary outcomes are changes in anxiety and depression scores at 6 weeks, while secondary outcomes include changes in quality of life and biomarkers. The study follows strict data management and confidentiality procedures throughout the trial.

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN is a very rare blood cancer with no agreed-upon best treatment. Researchers are working internationally to gather detailed information on how BPDCN presents, how it is diagnosed, the treatments patients receive, and their outcomes. The study aims to build a large database to better understand the disease and to develop treatment recommendations based on collected data. This study is an international registry collecting information from multiple centers about patients diagnosed with BPDCN. It includes both retrospective and prospective data from patients worldwide. The data collected covers patient details, disease characteristics, treatment information, outcomes, causes of death, and the conclusion of data collection. Consent will be obtained from prospective patients, and quality control is managed by the Immune Oncology Research Institute. Participants will provide information through questionnaires completed by their treatment centers. Researchers will analyze overall survival, complete remission rates, duration of first remission, and event-free survival over five years. This observational study does not involve treatment but gathers and monitors detailed clinical data to improve understanding and guide future therapies for BPDCN.

This research aims to study the short- and long-term effects of adding a comprehensive fall prevention program to regular physiotherapy for elderly women who have undergone total knee replacement TKR due to osteoarthritis. It focuses on reducing the number of falls, improving balance, and enhancing functional ability. The study is a single-blinded, randomized controlled trial lasting 24 weeks, involving older adults treated at Al-Razi Orthopedic Hospital. Participants will be divided into two groups. The control group will receive conventional physiotherapy that includes exercises to improve blood circulation, strengthen muscles, increase knee range of motion, and gait training. The experimental group will receive the same physiotherapy plus a fall prevention program featuring Otago balance exercises, personalized advice on assistive devices based on balance scores, environmental hazard checks, and guidance on vision care and footwear. Both groups will follow a home exercise program. During the study, participants will be monitored for falls at baseline, 12 weeks, and one year. Assessments will include knee range of motion and patient satisfaction at 12 weeks and one year. Adherence to the exercise programs will also be tracked. The trial aims to evaluate how well the combined treatment improves outcomes compared to physiotherapy alone, with safety and functional recovery closely observed throughout the study period.

Metabolic dysfunction-associated steatotic liver disease MASLD, previously called non-alcoholic fatty liver disease NAFLD, is a common chronic liver condition linked to obesity, diabetes, and dyslipidemia. This condition ranges from simple fat buildup in the liver to more severe forms like metabolic dysfunction-associated steatohepatitis MASH, which can cause liver injury, advanced fibrosis, cirrhosis, or liver cancer. Patients with MASH also face risks of cardiovascular disease and death. Currently, there is no universally approved medication for MASH, and weight loss remains the main treatment approach. This study is a randomized controlled trial comparing two treatments for adults with obesity and biopsy-confirmed MASH and liver fibrosis. Participants will be randomly assigned to receive either metabolic surgery including Roux-en-Y Gastric Bypass or Sleeve Gastrectomy or medical treatment using incretin-based therapies such as liraglutide, semaglutide, or tirzepatide. The study will follow participants for two years, after which a repeat liver biopsy will assess changes in liver fibrosis and MASH. Participants will undergo a baseline liver biopsy if none is available, followed by treatment with either surgery or medication. Throughout the two-year study, they will be monitored regularly, with assessments including liver biopsies to measure fibrosis improvement or progression, resolution of MASH, weight changes, and quality of life. Safety and treatment adherence will also be tracked to understand the impact of these interventions on liver health and overall well-being.

Researchers are tracking the natural history and clinical outcomes of patients with Gaucher disease through the ICGG Gaucher Registry, an international, multi-center observational program. This registry does not involve any experimental treatments, but collects information to better understand the variability, progression, and identification of Gaucher disease, aiming to improve patient care and therapeutic guidance. It also evaluates the long-term use of treatments like imiglucerase and eliglustat. The study includes two groups patients with Gaucher disease who receive routine clinical assessments and standard care as determined by their physicians, and a Pregnancy Sub-registry for women with Gaucher disease who are pregnant or have been pregnant. The Pregnancy Sub-registry collects information on pregnancy outcomes, complications, and infant growth up to 36 months postpartum, regardless of whether the women receive disease-specific therapy. Participants undergo clinical assessments and receive care according to their treating physicians decisions. Data collected includes medical history, pregnancy and birth details for the sub-registry, and patient outcomes over time. The primary goals are to provide recommendations for monitoring Gaucher disease patients, report outcomes to optimize care, and track pregnancy and infant growth outcomes. This ongoing registry allows long-term follow-up without experimental interventions.

Researchers are conducting the INTERSTELLAR study to gather important real-world evidence about adding anifrolumab to the usual treatment for systemic lupus erythematosus SLE. This observational study is taking place across multiple countries, including regions like GCC, Mexico, Central America, Colombia, Argentina, Taiwan, and Egypt. It aims to provide data useful for doctors, payers, and patients by using consistent criteria and measures for SLE and skin symptoms related to lupus. Participants will be observed for one year before starting anifrolumab and followed for one year after beginning treatment. The study starts after anifrolumabs commercial launch in each country and includes patients from the time of their first anifrolumab prescription and infusion. Data collection continues even if participants stop taking anifrolumab, unless they withdraw their consent. During the study, clinical assessments and patient-reported outcomes will be collected at baseline and at months 1, 3, 6, and 12. These include disease activity scores PGA, SLEDAI-2K, skin involvement measures CLASI, fatigue assessments FACIT-Fatigue, and quality of life questionnaires LupusQoL, EQ-5D-5L. The study monitors participants until death, loss to follow-up, withdrawal, or study end, aiming to reflect real-world use and outcomes of anifrolumab in routine care.

Researchers are conducting a follow-up study on the Kuwait Diabetes Epidemiology Program KDEP to better understand the risk factors leading to the onset of prediabetes and progression to type 2 diabetes T2D and related complications. This study focuses on the Kuwaiti population, a group with a high prevalence of obesity, diabetes, and metabolic disorders, and aims to gather detailed physiological, genetic, biochemical, and environmental data. The study also includes family members of original participants to explore familial patterns in diabetes risk. Participants from the original KDEP cohort who were non-diabetic, as well as other high-risk individuals, will be included. The study involves assessing participants with oral glucose tolerance tests OGTT and other detailed biochemical and molecular evaluations to identify factors associated with the development of diabetes and its vascular complications. A subset of around 250 participants will receive additional specialized testing such as hyperglycemia clamp and euglycemic clamp procedures. During the study, participants will be monitored over 4 to 7 years to determine the incidence of diabetes and prediabetes, as well as microvascular and macrovascular complications. Researchers will collect data through blood glucose measurements, HbA1C levels, and detailed clinical evaluations. The study aims to support the development of prevention strategies and health promotion programs in Kuwait by providing data on diabetes progression and associated risk factors. The total participation duration may extend up to five years for outcome assessment.

Researchers are evaluating whether resistance exercise and increased protein intake can help preserve lean muscle mass and improve physical function in people with obesity who are starting treatment with semaglutide or tirzepatide. The study aims to measure the impact of these interventions on muscle mass, physical function, and related health factors such as blood sugar control, liver function, and quality of life during weight loss induced by these medications. Participants will begin semaglutide or tirzepatide therapy, starting at a low dose and gradually increasing to maximize weight loss. They will be randomly assigned to one of four groups a control group maintaining usual exercise habits, a protein intake group aiming for 1.6gkgday of protein through protein drinks and diet adjustments, a resistance exercise group performing supervised exercises three times weekly, or a combined resistance exercise and protein intake group. The resistance exercise includes supervised and group sessions to ensure proper technique and progression. During the six-month study, participants will undergo various assessments including MRI scans to measure muscle and liver fat, body composition scans, muscle strength tests, and evaluations of physical activity, sleep quality, and quality of life. Blood tests will monitor blood sugar control, liver function, and inflammation markers. Researchers will track dietary intake and medication use throughout the study to understand the effects of the interventions on overall health and physical function.

This research aims to collect detailed information about Pompe disease, a rare genetic disorder also known as Glycogen Storage Disease Type II. The study is a global, long-term observational program designed to better understand the diseases progression, variability, and identification in patients who are either treated or untreated. It also supports regulatory requirements, product development, reimbursement, and other research purposes. Participants in the Pompe Registry are tracked over many years, up to 30 years, to observe the natural history of the disease and evaluate long-term outcomes, including the effects of treatments like alglucosidase alfa. This observational study does not involve experimental treatments but gathers data from patients worldwide to improve care strategies and recommendations. During the study, participants health information is collected retrospectively and prospectively, including clinical outcomes and disease manifestations. Researchers analyze these data to understand patient variability, disease progression, and treatment effectiveness. The registry helps develop guidance for monitoring patients and provides valuable insights to optimize Pompe disease care over an extended period.